References
- Leslie NR, Biondi RM, Alessi DR. Phosphoinositide-regulated kinases and phosphoinositide phosphatases. Chem Rev 2001; 101:2365 - 80; http://dx.doi.org/10.1021/cr000091i; PMID: 11749378
- Takahashi-Yanaga F. Activator or inhibitor? GSK-3 as a new drug target. Biochem Pharmacol 2013; 86:191 - 9; http://dx.doi.org/10.1016/j.bcp.2013.04.022; PMID: 23643839
- Sajithlal GB, Hamed HA, Cruickshanks N, Booth L, Tavallai S, Syed J, Grant S, Poklepovic A, Dent P. Sorafenib/regorafenib and phosphatidyl inositol 3 kinase/thymoma viral proto-oncogene inhibition interact to kill tumor cells. Mol Pharmacol 2013; 84:562 - 71; http://dx.doi.org/10.1124/mol.113.088005; PMID: 23877009
- Rahmani M, Aust MM, Attkisson E, Williams DC Jr., Ferreira-Gonzalez A, Grant S. Dual inhibition of Bcl-2 and Bcl-xL strikingly enhances PI3K inhibition-induced apoptosis in human myeloid leukemia cells through a GSK3- and Bim-dependent mechanism. Cancer Res 2013; 73:1340 - 51; http://dx.doi.org/10.1158/0008-5472.CAN-12-1365; PMID: 23243017
- Maris JM. Recent advances in neuroblastoma. N Engl J Med 2010; 362:2202 - 11; http://dx.doi.org/10.1056/NEJMra0804577; PMID: 20558371
- Franks LM, Bollen A, Seeger RC, Stram DO, Matthay KK. Neuroblastoma in adults and adolescents: an indolent course with poor survival. Cancer 1997; 79:2028 - 35; http://dx.doi.org/10.1002/(SICI)1097-0142(19970515)79:10<2028::AID-CNCR26>3.0.CO;2-V; PMID: 9149032
- Carter YM, Kunnimalaiyaan S, Chen H, Gamblin TC, Kunnimalaiyaan M. Specific glycogen synthase kinase-3 inhibition reduces neuroendocrine markers and suppresses neuroblastoma cell growth. Cancer Biol Ther 2014; 15:510 - 5; http://dx.doi.org/10.4161/cbt.28015; PMID: 24521712
- Madhunapantula SV, Sharma A, Gowda R, Robertson GP. Identification of glycogen synthase kinase 3α as a therapeutic target in melanoma. Pigment Cell Melanoma Res 2013; 26:886 - 99; http://dx.doi.org/10.1111/pcmr.12156; PMID: 24034838
- Bilim V, Ougolkov A, Yuuki K, Naito S, Kawazoe H, Muto A, Oya M, Billadeau D, Motoyama T, Tomita Y. Glycogen synthase kinase-3: a new therapeutic target in renal cell carcinoma. Br J Cancer 2009; 101:2005 - 14; http://dx.doi.org/10.1038/sj.bjc.6605437; PMID: 19920820
- Ahn SW, Kim JE, Park KS, Choi WJ, Hong YH, Kim SM, Kim SH, Lee KW, Sung JJ. The neuroprotective effect of the GSK-3β inhibitor and influence on the extrinsic apoptosis in the ALS transgenic mice. J Neurol Sci 2012; 320:1 - 5; http://dx.doi.org/10.1016/j.jns.2012.05.038; PMID: 22698482
- Westhoff MA, Faham N, Marx D, Nonnenmacher L, Jennewein C, Enzenmüller S, Gonzalez P, Fulda S, Debatin KM. Sequential dosing in chemosensitization: targeting the PI3K/Akt/mTOR pathway in neuroblastoma. PLoS One 2013; 8:e83128; http://dx.doi.org/10.1371/journal.pone.0083128; PMID: 24391739